medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2022, Number 1

<< Back Next >>

Rev Nefrol Dial Traspl 2022; 42 (1)

Prognostic value of kidney involvement in COVID-19

Fragale G, Tisi BM, Magenta M, Beitia V, Karl A, Rodríguez CL, Pousa V

Language: Spanish
References: 24
Page: 4-10
PDF size: 187.06 Kb.


ABSTRACT

Introduction: Acute kidney injury is a complication described in patients with SARS-CoV-2 infection that is around 0.5-7% of cases. Objective: evaluate the prognostic value of kidney involvement in patients hospitalized for COVID-19 disease. Methods: A prospective cohort of patients over 18 years with a diagnosis of COVID-19 disease in the period from May to October 2020 was analyzed. All were followed up until hospital discharge or death. Clinical and biochemical parameters, Charlson score, mortality and severity of COVID-19 disease were evaluated. Results: Four hundred twelve patients entered the study, 57% men and mean age 51 ± 16 years. Twenty percent had a Charlson score ≥3, the incidence of acute kidney injury, defined as the increase in serum creatinine 0.3 mg / dl from baseline, was 5.5% (n = 23) and hospital mortality was 2.2% (n = 9). The bivariate and multivariate analysis showed that the male sex [OR= 0.32 (IC 0.12-0.82), p = 0.017], D-dimer› 500 ng/ml [OR= 3.68 (IC 1.23- 10.96), p = 0.019], urinary protein/creatinine › 0.20 [OR= 2.43 (CI 1.03-5.74), p = 0.043], and AKI [OR= 10.53 (CI 2.99-37.09), p ‹0.0001] were predictors of severe COVID-19, defined as respiratory rate ›30 x min, oxygen saturation <93% or PO2/FIO2 ‹300. The univariate analysis of mortality was associated with the development of severe COVID-19 [OR= 68.76 (CI 8.39-563.36), p ‹0.0001] and acute kidney injury [OR= 45.41 (CI 10.45-197.22), p ‹0.0001]. Conclusion: Renal involvement is associated with worse evolution and higher mortality in COVID-19. The assessment of renal function and proteinuria are accessible parameters that should be included as risk factors in the initial evaluation of these patients.


REFERENCES

  1. World Health Organization. Coronavirus disease 2019(COVID-19) [Internet]. Situation Report. 2020;56.Disponible en: (consulta: 15/03/2021).

  2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y,et al. Clinical features of patients infected with2019 novel coronavirus in Wuhan, China. Lancet.2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.

  3. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al.Clinical characteristics of 138 hospitalized patientswith 2019 novel coronavirus-infected pneumonia inWuhan, China. JAMA. 2020;323(11):1061-9. doi:10.1001/jama.2020.1585.

  4. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX,et al.; China Medical Treatment Expert Group forCOVID-19. Clinical characteristics of coronavirusdisease 2019 in China. N Engl J Med. 2020;382(18):1708-20. doi: 10.1056/NEJMoa2002032.

  5. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al.Comorbidities and multi-organ injuries in the treatmentof COVID-19. Lancet. 2020;395(10228):e52. doi:10.1016/S0140-6736(20)305584.

  6. Cheng Y, Luo R, Wang K, Zhang M, Wang Z,Dong L, et al. Kidney disease is associated with inhospitaldeath of patients with COVID-19. Kidney Int.2020;97(5):829-38. doi: 10.1016/j.kint.2020.03.005.

  7. Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al.Coronavirus disease 19 infection does Not result inacute kidney injury: an analysis of 116 hospitalizedpatients from Wuhan, China. Am J Nephrol.2020;51(5):343-8. doi: 10.1159/000507471.

  8. Abbate M, Rottoli D, Gianatti A. COVID-19 attacksthe kidney: ultrastructural evidence for the presenceof virus in the glomerular epithelium. Nephron.2020;144(7):341-2. doi: 10.1159/000508430.

  9. Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, etal. Renal histopathological analysis of 26 postmortemfindings of patients with COVID-19 in China.Kidney Int. 2020;98(1):219-27. doi: 10.1016/j.kint.2020.04.003.

  10. Lim JH, Park SH, Jeon Y, Cho JH, Jung HY, ChoiJY, et al. Fatal outcomes of COVID-19 in patientswith Severe Acute Kidney Injury. J Clin Med.2020;9(6):1718. doi: 10.3390/jcm9061718.

  11. Peng S, Wang HY, Sun X, Li P, Ye Z, Li Q, et al. Earlyversus late acute kidney injury among patients withCOVID-19-a multicenter study from Wuhan, China.Nephrol Dial Transplant. 2020;35(12):2095-102. doi:10.1093/ndt/gfaa288.

  12. Diagnosis and treatment protocol for novelcoronavirus pneumonia (trial version 7). ChinMed J (Engl). 2020;133(9):1087-95. doi: 10.1097/CM9.0000000000000819.

  13. Charlson ME, Pompei P, Ales KL, MacKenzie CR.A new method of classifying prognostic comorbidityin longitudinal studies: development and validation.J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.

  14. Kellum JA, Lameire N, Aspelin P, MacLeod AM,Barsoum RS, Mehta RL, et al. Kidney Disease:Improving Global Outcomes (KDIGO) AcuteKidney Injury Workgroup. KDIGO clinical practiceguideline for acute kidney injury. Kidney Int Suppl.2012;2(1):1-138.

  15. Argentina. Ministerio de Salud. Recomendacionescondicionales para el abordaje terapéutico de COVID-19[Internet]. Disponible en: (consulta:15/03/2021).

  16. Robbins-Juarez SY, Qian L, King KL, Stevens JS,Husain SA, Radhakrishnan J, et al. Outcomes forpatients with COVID-19 and acute kidney injury: asystematic review and meta-analysis. Kidney Int Rep.2020;5(8):1149-60. doi: 10.1016/j.ekir.2020.06.013.

  17. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structuralbasis for the recognition of SARS-CoV-2 by full-lengthhuman ACE2. Science. 2020;367(6485):1444-8. doi:10.1126/science.abb2762.

  18. Hamming I, Timens W, Bulthuis ML, Lely AT, NavisG, van Goor H. Tissue distribution of ACE2 protein,the functional receptor for SARS coronavirus. A firststep in understanding SARS pathogenesis. J Pathol.2004;203(2):631-7. doi: 10.1002/path.1570.

  19. Cheng Y, Luo R, Wang K, Zhang M, Wang Z,Dong L, et al. Kidney disease is associated with inhospitaldeath of patients with COVID-19. Kidney Int.2020;97(5):829-38. doi: 10.1016/j.kint.2020.03.005.

  20. Moreno G, Carbonell R, Bodí M, RodríguezA. Systematic review of the prognostic utility ofD-dimer, disseminated intravascular coagulation,and anticoagulant therapy in COVID-19 critically illpatients. Med Intensiva (Engl Ed). 2021;45(1):42-55.doi:10.1016/j.medin.2020.06.006.

  21. Sultan S, Altayar O, Siddique SM, Davitkov P,Feuerstein JD, Lim JK, et al. AGA Institute rapidreview of the gastrointestinal and liver manifestationsof COVID-19, meta-analysis of international data, andrecommendations for the consultative managementof patients with COVID-19. Gastroenterology.2020;159(1):320-334.e27. doi: 10.1053/j.gastro.2020.05.001.

  22. Hundt MA, Deng Y, Ciarleglio MM, NathansonMH, Lim JK. Abnormal liver tests in COVID-19:a retrospective observational cohort study of 1,827patients in a Major U.S. Hospital Network. Hepatology.2020;72(4):1169-76. doi: 10.1002/hep.31487.

  23. Mendizabal M, Piñero F, Ridruejo E, AndersM, Silveyra MD, Torre A, et al. Prospective LatinAmerican cohort evaluating outcomes of patients withCOVID-19 and abnormal liver tests on admission.Ann Hepatol. 2021;21:100298. doi: 10.1016/j.aohep.2020.100298.

  24. Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY,Yi F, Yang HC, Fogo AB, Nie X, Zhang C. Renalhistopathological analysis of 26 postmortem findingsof patients with COVID-19 in China. Kidney Int.2020;98(1):219-27. doi: 10.1016/j.kint.2020.04.003.




2020     |     www.medigraphic.com